Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intravenous glycoprotein inhibitor + acetylsalicylic acid + clopidogrel
- Development stage
- Unknown
- Lead developer
- Icahn School of Medicine
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is an aggressive antiplatelet regimen evaluated in the RESIST trial by the Icahn School of Medicine at Mount Sinai. It consists of an intravenous glycoprotein IIb/IIIa inhibitor (such as abciximab, eptifibatide, or tirofiban) added to standard oral dual antiplatelet therapy (DAPT) comprising acetylsalicylic acid (aspirin) and clopidogrel. The regimen was specifically studied in aspirin-resistant patients with stable angina undergoing percutaneous coronary intervention (PCI) to reduce the risk of periprocedural ischemic events. The GP IIb/IIIa inhibitor blocks the final common pathway of platelet aggregation by targeting the integrin alpha-IIb/beta-3 receptor, while aspirin inhibits cyclooxygenase-1 (COX-1) and clopidogrel antagonizes the P2Y12 receptor.
- Other names
- Aggressive antiplatelet therapyTriple antiplatelet therapy (GP IIb/IIIa inhibitor + ASA + clopidogrel)
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)PGHS-1 (Prostaglandin G/H Synthase 1)P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on intravenous glycoprotein inhibitor + acetylsalicylic acid + clopidogrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intravenous glycoprotein inhibitor + acetylsalicylic acid + clopidogrel.